My research examines molecular determinants of smoking cessation combining formal skill sets in medicine, public health, pharmacogenetics/pharmacogenomics, and functional neuroimaging. I have conducted pharmacogenetics studies of nicotine replacement therapy and bupropion for smoking cessation, finding significant gene x treatment interactions for bupropion and identifying mediating pathways for bupropion smoking cessation efficacy. The overall goal is to translate this research to practice.
Dr. David is Director of Research in Family Medicine. His research spans the translational continuum from molecular genetics to health policy and is focused on smoking cessation. Recently published studies have identified genetic (pharmacogenetic and pharmacogenomic) influences on drug response to bupropion and nicotine replacement therapy for smoking cessation and have examined brain reward pathways using functional neuroimaging. He is actively translating these data into practice and policy through cost-effectiveness analyses, meta-analyses, and medical informatics working with a Trans-Atlantic transdisciplinary research team. He is also active in clinical practice and education.
SEAN DAVID, MD, SM, DPhil
On The Web:
Primary Care Genetics Laboratory and Translational Research Center
Collaborators at other institutions:
Are you Sean David? Click here to edit your research profile.